The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers
unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main …

Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery,
chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC …

Anaplastic thyroid cancer (ATC) is one of the most lethal of all cancers. It is more common in
women and occurs primarily in older patients. ATC has a median overall survival of 3–5 …

Background: Very little was known about the molecular pathogenesis of thyroid cancer until
the late 1980s. As part of the Centennial celebration of the American Thyroid Association …

Differentiated thyroid cancers (DTCs) are primarily initiated by mutations that activate the
MAPK signaling cascade, typically at BRAF or RAS oncoproteins. DTCs can evolve to more …

Background: BRAFV600E and N/H/K RAS mutations and oncogenic kinase fusions
involving neurotrophin tyrosine receptor kinase (NTRK), RET, anaplastic lymphoma kinase …

Over the past 3 decades, advances in the molecular genetics of thyroid cancer (TC) have
been translated into diagnostic tests, prognostic markers, and therapeutic agents. The main …

Aims Anaplastic thyroid cancer (ATC) is a rare but aggressive form of thyroid cancer with a
median survival of 4 months. Recent advances in molecular profiling have shown that up to …

Molecular diagnostic testing has had a profound impact on the diagnosis and management
of thyroid nodules and thyroid cancer. Based on the tremendous expansion of knowledge of …

The use of radioiodine therapy (RIT) is debated in intermediate-risk differentiated thyroid
cancer (DTC) patients. The understanding of the molecular mechanisms involved in the …